Deutsche Bank AG Acquires 1,106,696 Shares of Bristol Myers Squibb Company $BMY

Deutsche Bank AG boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 12.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,143,181 shares of the biopharmaceutical company's stock after buying an additional 1,106,696 shares during the quarter. Deutsche Bank AG owned approximately 0.50% of Bristol Myers Squibb worth $584,450,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Bayban bought a new stake in Bristol Myers Squibb during the fourth quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on BMY. Cantor Fitzgerald reiterated a "neutral" rating and issued a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Roth Capital initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price objective on the stock. Weiss Ratings upgraded shares of Bristol Myers Squibb from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, July 30th. TD Cowen began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating for the company. Finally, Citigroup reaffirmed a "neutral" rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $64.71 on Tuesday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The company has a market cap of $132.18 billion, a PE ratio of 14.25, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The business has a 50-day simple moving average of $59.75 and a two-hundred day simple moving average of $59.06.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source